Authors

Bo Fu, Yong Xiamei, Beilei lin, Suyan Chen, Peng Wang, Yawen Guo, Yongli Wang, Qiushi Zhang, Bei Qi, Zhenxiang Zhang#

Departments

School of Nursing and Health, Zhengzhou University, Zhengzhou, Henan, P.

Abstract

Introduction: Tissue hypoxia is a critical factor in ischaemic cell death. Oxygen therapy can increase the oxygen supply of ischemic brain tissue and improve ischemia-reperfusion injury. However, hyperbaric oxygen has deficiencies in the treatment of patients with acute ischaemic stroke. Additionally, normobaric oxygen (NBO) is controversial in the treatment of acute ischaemic stroke patients. Therefore, this study aims to analyse current data of NBO treatment on acute ischaemic stroke patients as used in the clinic.

Materials and methods: We searched for relevant articles from, China National Knowledge Infrastructure (CNKI), Chongqing VIP Database (VIP), WanFang Database, PubMed, Embase, and Cochrane that were published prior to June 2017. Articles of randomized controlled trials to assess the effect of NBO on patients with acute ischaemic stroke were included.

Results: Six articles involving 292 participants were included in this systematic review. In the included studies, three articles had a low risk of bias and were A-level evidence, and the other studies had a higher risk of bias and were only B-level evidence. Compared to controls, NBO induced more improvement in neurological recovery after stroke based on the NIHSS scale. Additionally, NBO improved daily living ability and disability of patients, but the long-term effects were not obvious. In contrast, because of the limited number of studies included, we found that NBO has no effect on the recurrence rate and mortality of patients with acute ischaemic stroke. Additionally, NBO therapy at 45 L/min is superior to other concentrations of oxygen therapy. 

Conclusion: These results indicate that NBO can improve the health status of patients with acute ischaemic stroke. 

Keywords

Normobaric oxygen therapy, Acute ischaemic stroke, Systematic review.

DOI:

10.19193/0393-6384_2019_6_517